Blunt Business

As the legal cannabis sector eagerly awaits federal reclassification judgments, industry players are aggressively pivoting toward untapped markets and hesitant, first-time consumers. In California, dispensaries are tearing down old retail friction points by introducing state-approved self-checkout kiosks equipped with multi-product RFID scanners, mimicking the familiarity and efficiency of traditional supermarket shopping. Simultaneously, New York is expanding access points into everyday public life by enacting legislation that allows small cannabis businesses to sell directly at local farmers' markets. By combining friction-free retail automation with accessible, community-based storefronts, the industry is reshaping its sales funnel to court a brand-new demographic—consumers who have never stepped foot inside a dispensary, but are now ready to engage on their own terms.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Although the historic DEA rescheduling hearings have officially concluded, the administrative process has ended without an immediate, final ruling, leaving the federal status of cannabis temporarily in limbo. Despite the lack of a definitive outcome, the hearings marked a monumental breakdown in federal policy: medical cannabis operators are emerging as clear near-term winners due to the immediate relief from Section 280E tax burdens and expedited DEA registration opportunities, while the broader adult-use sector remains caught between federal delays and potential legal challenges. Operators are now urged to take swift, strategic action—from restructuring tax methodologies to preparing for stricter federal compliance—rather than passively waiting on a binding decision that could face lengthy court battles.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

As the DEA moves toward rescheduling cannabis, the industry is bracing for a complex transformation defined by regulatory uncertainty and potential legal headwinds. While federal agencies have taken an unexpectedly active role in supporting this transition, the timeline for full implementation remains long and subject to likely legal challenges. Blunt Business speaks with Chris Lynch, partner at Dickinson Wright to chime in. For businesses, the landscape is currently defined by heavy operational burdens, such as state-specific excise taxes and residency requirements; however, upcoming shifts like Section 280E relief and the prospect of federal trademark protection signal a turning point. Looking ahead, stakeholders anticipate a wave of consolidation and capital infusion that will redefine the market, even as they remain cautious of looming legislative pushback and the potential impacts of hemp reclassification.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Joe Bayern with MM Brands outlines a strategic roadmap for professionalizing the cannabis industry, emphasizing that sustainable growth requires moving beyond fragmented operations. Key strategies include adopting a portfolio-based management model to share operational and manufacturing costs, implementing minimalist, needs-based branding to simplify the consumer experience, and navigating regulatory hurdles through omnichannel agility. Furthermore, Bayern advocates for a "one plant" regulatory framework and anticipates continued industry consolidation, noting that businesses must modernize their supply chains to drive the quality, consistency, and therapeutic reliability essential for long-term mainstream adoption.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Blunt Business welcomes Joe Bayern, the CEO of MM Brands to discuss how the cannabis industry is approaching a potential turning point as DOJ and DEA hearings conclude this July, with anticipation high for a move to Schedule 3 classification. This reclassification could eliminate 280E tax constraints, driving better profitability, while FDA validation of therapeutic benefits promises to reduce stigma and build consumer trust. Despite this momentum, the sector faces significant headwinds, specifically a critical shortage of experienced middle management and the ongoing difficulty of maintaining quality control and compliance amidst fragmented, state-specific regulations.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Once again we welcome back Nick Richards, Partner and co-chair of the cannabis law practice group at Greenspoon Marder about how the cannabis and hemp industries currently face a complex landscape defined by existential regulatory threats and critical federal proceedings. Financial institutions are increasingly wary, with potential hemp reclassification jeopardizing banking access and subjecting businesses to high-risk compliance hurdles.Meanwhile, industry experts are closely monitoring the upcoming DOJ administrative hearings, which represent a pivotal, though non-binding, opportunity to challenge Schedule I status for cannabis. Despite concerns over limited transparency and the exclusion of key industry advocacy groups, the strategy remains to leverage scientific evidence over political rhetoric to push for federal rescheduling.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

The sports industry is witnessing a landmark normalization of cannabis, highlighted by the WNBA’s recent collective bargaining agreement which removed cannabis from its prohibited substances list in favor of supportive substance abuse treatment programs. While this signals a new era for athlete endorsements and professional branding, the broader cannabis and hemp sector faces a precarious future. Blunt Business speaks with Nick Richards, Partner and co-chair of the cannabis law practice group at Greenspoon Marder.Businesses are currently bracing for a November 12th federal deadline that could redefine “illegal hemp,” potentially outlawing 95% of current CBD products and creating significant financial and regulatory hurdles, including the looming threat of Section 280E tax penalties.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

We report on a wave of highly targeted legislative, legal, and medical updates aimed at curbing market disorder and protecting public health.In the United States, Virginia has advanced a budget deal to its governor establishing a definitive July 2027 timeline for adult-use dispensary sales, while Illinois has enacted precise safety guardrails by banning intoxicating hemp sales to minors and enforcing strict child-proof packaging. This regulatory tightening faces immediate constitutional hurdles in the courts, where Ninth Circuit judges are currently deadlocked over whether sweeping state bans on cannabis billboard advertisements violate free speech.Meanwhile, international markets are facing severe enforcement crises; Thailand’s Ministry of Public Health has rolled out an aggressive penalty framework targeting rule-breaking dispensaries with immediate license suspensions, and Canada’s regulated sector is suffering such severe economic pressure from a deeply entrenched illicit market that a major national cannabis organization was forced to suspend its operations.Underpinning these legislative shifts is an escalating medical concern highlighted by The Epoch Times, which details how high-potency THC stores itself long-term in bodily fat and organs, continuously triggering low-grade, system-wide immune inflammation even after active consumption stops.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Dr. Priyanka Sharma, co-CEO of Kazmira Therapeutics and fellow co-CEO Pulak Sharma, cut through the confusion surrounding the rapidly evolving cannabis and hemp sectors. She clarifies the critical distinction between THCA—the non-intoxicating precursor that converts to THC upon heating—and delta-9 THC, noting that current marketing often masks the potential intoxicating effects of heated THCA products. Dr. Sharma also unpacks the implications of the Schedule III reclassification, explaining why it creates a distinct "two-lane system" for medical cannabis versus industrial hemp rather than a blanket regulatory change.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Kazmira Therapeutics is revolutionizing the CBD landscape by transitioning cannabinoids from over-the-counter health supplements to precision, pharmacist-compounded "real medicine". Led by co-founders Dr. Priyanka Sharma and Pulak Sharma, the company leverages proprietary precision-chemistry—rooted in her background as a chemical engineer—to ensure zero-THC, high-purity formulations. This clinical approach is increasingly relevant against the backdrop of significant regulatory changes, including the Schedule III reclassification of medical cannabis and recent federal legislation that further defines industrial hemp and hemp-derived cannabinoid products. These regulatory developments, which establish clearer standards such as a 0.4mg total THC limit, are dismantling the market's reliance on the confusing 0.3% dry-weight loophole and creating a "two-lane system" that prioritizes clinically supported, regulated products over speculative supplements.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

As a massive federal hammer prepares to fall on the hemp industry, progressive states are throwing operators a regulatory lifeline—just as the legal cannabis market faces its own "Big Tobacco" reckoning.A newly filed federal class-action lawsuit targets major Chicago-based operators like Cresco Labs and Green Thumb Industries, accusing them of "Big Tobacco"-style deceptive marketing that downplays the psychotropic risks of high-THC products. Yet, against this turbulent backdrop, Midwestern lawmakers are aggressively reshaping the market. Facing a looming November 2026 federal ban on potent hemp products, Minnesota has enacted a landmark omnibus bill that allows hemp business owners to dual-license and pivot directly into the regulated cannabis market. Similarly, Illinois lawmakers are advancing a massive industry overhaul (HB 5784) designed to ease financial burdens on smaller social equity operators while building parallel transitional pathways for hemp companies. By allowing these industries to consolidate, states are creating a vital legal gateway for hemp businesses to survive under the umbrella of the regulated cannabis market before federal workarounds vanish entirely.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Blunt Business zeroes in on major developments unfolding on the congressional front. It highlights how impending federal rescheduling could significantly alter medical cannabis policies within the Veterans Administration, potentially expanding access for military veterans by allowing VA doctors to discuss and document use, as well as refer patients to state-approved programs. Additionally, we break down the bipartisan BUILD Act (Building Unrivaled Infrastructure and Long-Term Development Act), a piece of transportation legislation moving toward a House floor vote. The bill directives mandate federal agencies to invest $110 million to research poly-substance impairment and establish standardized, evidence-based driving limits, addressing the long-standing scientific flaws and regional inconsistencies currently plaguing roadside testing.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

This week on Blunt Business, we’re diving into two massive legal shifts reshaping cannabis markets on opposite sides of the country. First, we break down Georgia’s major policy overhaul as Governor Brian Kemp signs the "Putting Georgia's Patients First Act."From expanding the list of qualifying conditions to include lupus, to lifting strict "end-stage" limitations and allowing adult vaping and edibles, the Peach State is dramatically widening medical access.Then, we pivot to Washington, D.C., where a high-stakes federal lawsuit challenging the District's cannabis licensing and enforcement system was suddenly dropped. We’ll analyze why the Alliance for Recreational Cannabis Entities voluntarily dismissed their case, how a recent federal appeals court ruling regarding the Dormant Commerce Clause triggered the move, and what this unresolved constitutional battle means for local market protections across the United States.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

As the federal government moves toward rescheduling marijuana, the cannabis industry is eyeing a massive financial shift: the potential for $15 billion in retroactive tax relief from Section 280E. While the transition to Schedule 3 offers a path to future profitability, businesses must act immediately to file protective claims before statutes of limitation expire.This economic evolution coincides with a significant demographic pivot, as older adults become the fastest-growing consumer group, frequently choosing edibles for pain and sleep management over pharmaceuticals.However, the move toward higher-potency THC products is a double-edged sword, with new studies linking high-strength medicinal cannabis to increased risks of anxiety and psychiatric side effects, underscoring the need for careful regulation and informed medical guidance.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

The potential move to Schedule III presents a massive financial opportunity for "Sin City," yet current local friction threatens to stall that momentum. As the federal government nears reclassification, the industry is at a crossroads between record-breaking growth and a cooling tourist market.While the city is built on "cashing in," Las Vegas could be losing tourists due to a recent crackdown on public consumption and strict enforcement. For the city to fully capitalize on the "Green Rush," it must reconcile its status as a global playground with the reality of a regulated cannabis market. If tourists feel penalized for legal use, they may take their gambling and entertainment dollars elsewhere.The shift to Schedule III is the "jackpot" many operators have been waiting for, primarily due to the removal of the 280E tax penalty. This change would allow businesses to finally treat cannabis like a standard industry, potentially injecting millions back into the local economy.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy